NCT00404495 - Combination of Irinotecan and Temozolomide in Children With Brain Tumors. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

January 31, 2011

Study Completion Date

December 31, 2011

Conditions

GliomaMedulloblastoma

Interventions

DRUG

Irinotecan

Irinotecan 10 mg/m\^2 per day on days 1-5 and days 8-12 in repeated 3 week cycles

DRUG

Temozolomide

Temozolomide 100-125 mg/m\^2 daily on days 1-5 in repeated 3 week cycles

Trial Locations (29)

2100

Pfizer Investigational Site, Koebenhavn OE

2145

Pfizer Investigational Site, Westmead

3000

Pfizer Investigational Site, Leuven

3052

Pfizer Investigational Site, Parkville

4029

Pfizer Investigational Site, Herston

8200

Pfizer Investigational Site, Aarhus N

9000

Pfizer Investigational Site, Ghent

13385

Pfizer Investigational Site, Marseille

28009

Pfizer Investigational Site, Madrid

30120

Pfizer Investigational Site, El Palmar

33000

Pfizer Investigational Site, Bordeaux

35100

Pfizer Investigational Site, Padua

41013

Pfizer Investigational Site, Seville

46026

Pfizer Investigational Site, Valencia

49000

Pfizer Investigational Site, Angers

59020

Pfizer Investigational Site, Lille

69373

Pfizer Investigational Site, Lyon

75005

Pfizer Investigational Site, Paris

94805

Pfizer Investigational Site, Villejuif

04-730

Pfizer Investigational Site, Warsaw

08035

Pfizer Investigational Site, Barcelona

08950

Pfizer Investigational Site, Esplugues de Llobregat

SO16 6YD

Pfizer Investigational Site, Soouthampton

B4 6NH

Pfizer Investigational Site, Birmingham

LS9 7TF

Pfizer Investigational Site, Leeds

M27 4HA

Pfizer Investigational Site, Manchester

NE1 4LP

Pfizer Investigational Site, Newcastle upon Tyne

NG7 2UH

Pfizer Investigational Site, Nottingham

SM2 5PT

Pfizer Investigational Site, Sutton